Neurology News

Although it was well tolerated, the anti-amyloid antibody crenezumab did not reduce clinical decline in patients with Alzheimer's disease, researchers reported in JAMA Neurology.

A phase 3 trial that evaluated the safety and efficacy of the intrathecally administered antisense oligonucleotide tofersen reduced concentrations of superoxide dismutase 1 protein in patients with ALS who had mutations in the gene.

Fortunately, in recent years, migraine has gained wider public and provider recognition as a complex and serious, chronic neurological disease that can profoundly impact a person’s quality of life.

The FDA has approved Elucirem, a macrocyclic gadolinium-based contrast agent for those aged 2 years and older, for use in contrast-enhanced MRIs

In this edition, FDA votes to support approval of ALS therapy; partnership offers military veterans access to psychedelics; epidural steroid injections as alternate pain management options and more.

Acupuncture was shown to be an effective treatment for anxiety in patients with Parkinson’s disease, researchers reported in JAMA Network Open.

The FDA and NIH announced the launch of the Critical Path for Rare Neurodegenerative Diseases, a public-private partnership aimed to advance the understanding of neurodegenerative diseases and the development of treatments.

Maintaining a balanced energy intake through diet was associated with significantly better cognitive function compared with uneven intake patterns, researchers reported in Life Metabolism.

Alzheon Inc. reported statistically significant and clinically relevant results in patients with Alzheimer’s disease following 12 months of treatment with the oral investigational therapeutic ALZ-801 in its phase 2 trial.

Six metabolites — four related to sugar — were consistently associated with lower global cognitive function, researchers reported in Alzheimer’s & Dementia.